Pediatric brain stem tumors: identify molecular brake (IFNGR2) and acceleration agent (TGFB2) in the tumor environment, affecting the survival results
Children’s brain stem tumors are a major health problem, especially because they are difficult to treat and often lead to poor results. Understanding the genetic and molecular characteristics of these tumors can provide valuable information, which leads to better treatment strategies. By checking the specific marks in the tumor environment, researchers began to discover how these factors affect the survival results of young patients, so as to hope that more effective therapies will be provided in the future.
Researchers and Dr. Vuong Trieu, a researcher at the ONCotelic Therapeutics led by Dr. Sanjive Qazi and Dr. Zahra Talebi, revealed the key -related related survival of the MRNA level of specific biomarkers and the pervasive midline gel tumor (DMG) of the maternal logo. sex. Their research was published in biomedicine, providing a key insight for the impact of tumor microenvironment (TME) on the prognosis of the disease.
The group explores the expression curve of the TME TME Rotary Growth Factors β2 (TGFB2) and interferon γ receptor 2 (IFNGR2) of Pediatric DMG. This study aims to determine the potential biomarkers that can predict the survival results and provide information for the treatment strategy. The study analyzed the MRNA level in tumor samples and compared it with normal brain stem tissue, revealing significant discovery.
Dr. QAZI said: “High -level TGFB2 and IFNGR2 levels in the micro -environment of tumors are low, and the overall survival results are significantly worse.” “This indicates that TME’s immune suppression and tumor progress mechanism is crucial in patient prognosis. effect.”
Researchers have found that children’s brain stem DMG tumors show that the level of TGFB2 MRNA has increased, and compared with normal brain stem tissues, antigens such as CD14, CD163 and ITGAX/CD11C are reduced in expression of the cell (APC) marked. These marks are essential for immune system recognition and attack on tumor cells. The research results show that the level of high TGFB2 helps to immune to the “cold” tumor environment, thereby hindering the human body’s anti -tumor response.
In their analysis, the team uses a diverse COX proportional hazard modeling to evaluate the prognosis of TGFB2 and IFNGR2 expression levels. They found that high TGFB2 expression strongly predicts that the overall survival rate is poor, which has nothing to do with other factors (such as the age of patients and the interaction between TGFB2 and IFNGR2 levels).
Dr. QAZI pointed out: “Data shows that combining TGFB2 with the strategy of enhanced IFNGR2 signal transmission may improve the survival results of patients with DMG in children.” Immune response “
The study emphasizes the complexity of the TME of the brain stem in children’s DMG. It emphasizes not only the need for therapy for tumor cells, but also regulates the immune environment to enhance the human body’s natural defense ability to cancer. Researchers emphasize that future treatment methods may involve inhibiting the generation of TGFB2, while activating immune cells through IFN-γ stimulated.
Dr. QAZI said: “Our most important conclusion is that the role of TME in the DMG process is very important.” “Understanding these interactions at the molecular level has opened up new ways to develop targeted therapies that can improve patient prognosis.”
This study by Dr. QAZI, Dr. Talebi and Dr. Trieu marks an important step in the more effective treatment strategy for children’s DMG. This is a highly aggressive and challenging cancer. By identifying and targeting specific molecular pathways in TME, scientists hope to develop therapy can significantly extend the life of young patients who fight against this devastating disease.
Journal reference
QAZI, S., Talebi, Z. , & Trieu, V. (2024). The transforming growth factor β2 (TGFB2) and interferon γ receptor 2 (IFNGR2) MRNA level significantly affects the overall survival rate of patients DMG patients in the brain stem tumor microe environment (TME). Biomedical, 12 (1), 191. DOI:
